Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir in Brazilian HCV patients
NCT03219216Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of glecaprevir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jun 2018; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03219216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219216.